Tom van Meerten
Overview
Explore the profile of Tom van Meerten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
2111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, et al.
Lancet Oncol
. 2025 Feb;
26(2):200-213.
PMID: 39914418
Background: The combination of ibrutinib and venetoclax leverages complementary mechanisms of action and has shown promising clinical activity in mantle cell lymphoma (MCL). This study evaluated the efficacy and safety...
2.
Liebers N, Boumendil A, Finel H, Edelmann D, Kobbe G, Baermann B, et al.
Blood Cancer Discov
. 2025 Feb;
PMID: 39913291
Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an...
3.
Tienstra M, de Boer J, van Doesum J, Keijzer K, Morsink L, Hazenberg C, et al.
Endocr Pract
. 2024 Sep;
30(12):1141-1148.
PMID: 39332497
Objective: During intensive hematologic care, patients are exposed to high-dose chemotherapy, corticosteroids, immunosuppressants, and total parenteral nutrition. Combined with physiologic stress and increased release of cytokines and hormones, this can...
4.
de Groot D, Lub-de Hooge M, van Meerten T, Brouwers A, de Vries E
Clin Cancer Res
. 2024 Sep;
30(23):5252-5259.
PMID: 39325013
Current immunotherapies have brought major progress in cancer treatments, but not all patients benefit. Therefore, insight into reasons for treatment failure and optimal biomarkers for patient selection are warranted. Current...
5.
van Meerten T, Kuruvilla J, Song K, Thieblemont C, Minnema M, Forcade E, et al.
Am J Cancer Res
. 2024 Jul;
14(6):2905-2920.
PMID: 39005691
Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, was approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) based on the results from pivotal Cohorts 1+2 of ZUMA-1...
6.
Dreyling M, Doorduijn J, Gine E, Jerkeman M, Walewski J, Hutchings M, et al.
Lancet
. 2024 May;
403(10441):2293-2306.
PMID: 38705160
Background: Adding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed to...
7.
Lin Y, Choukrani G, Dubbel L, Rockstein L, Freile J, Qi Y, et al.
Exp Hematol Oncol
. 2024 Mar;
13(1):35.
PMID: 38553748
Background: VISTA is a well-known immune checkpoint in T cell biology, but its role in innate immunity is less established. Here, we investigated the role of VISTA on anticancer macrophage...
8.
Keijzer K, de Boer J, van Doesum J, Noordzij W, Huls G, van Dijk L, et al.
Blood Cancer J
. 2024 Mar;
14(1):41.
PMID: 38448432
Bridging therapy before CD19-directed chimeric antigen receptor (CAR) T-cell infusion is frequently applied in patients with relapsed or refractory Large B-cell lymphoma (r/r LBCL). This study aimed to assess the...
9.
Oluwole O, Forcade E, Munoz J, de Guibert S, Vose J, Bartlett N, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):366-372.
PMID: 38177222
ZUMA-1 safety management cohort 6 investigated the impact of prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab on the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs)...
10.
de Boer J, Keijzer K, Pennings E, van Doesum J, Spanjaart A, Jak M, et al.
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001703
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can hamper the clinical benefit of CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL). To...